Advances in early screening and diagnosis of prostate cancer.
- Author:
Ying-fan LI
1
;
Hong-xin LI
2
;
Wei-fu WANG
1
;
Fan-chang ZENG
1
Author Information
1. Department of Urology， Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University， Haikou， Hainan 570311， China.
2. The Second School of Clinical Medicine， Hainan Medical University， Haikou， Hainan 571199， China.
- Publication Type:Review
- MeSH:
Humans;
Male;
Benzhydryl Compounds/adverse effects*;
Drugs, Chinese Herbal/therapeutic use*;
Infertility, Male/chemically induced*;
Medicine, Chinese Traditional;
Phenols/adverse effects*;
Testis/drug effects*;
Bisphenol A Compounds
- From:
National Journal of Andrology
2025;31(5):462-468
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is one of the most common tumor, with the disease progressing from inert to aggressive tumors, and rapidly progressing to castration-resistant prostate cancer. Early-stage prostate cancer is usually asymptomatic. And by the time that symptoms appear, the disease has progressed to an incurable stage. Therefore, early diagnosis and treatment is especially important to control prostate cancer, which prolongs the survival period of patients. Digital rectal examination and prostate-specific antigen have been widely used in the diagnosis of prostate cancer. However, there are certain limitations that lead to overdiagnosis and overtreatment. Although prostate needle biopsy is still the gold standard for diagnosing prostate cancer, with the wide application of multiparametric magnetic resonance examination and PSMA-PET/CT and other technologies in recent years, as well as the emergence of new biomarkers with higher sensitivity and specificity, its status as the gold standard has been challenged. And the diagnostic mode of prostate cancer has also undergone great changes. On this basis, the radical prostatectomy without prostate needle biopsy has been attempted clinically to treat prostate cancer, which gains the good clinical results. This article provides a review of the latest research advances in early screening and diagnostic models for prostate cancer.
